RU2017134055A3 - - Google Patents

Download PDF

Info

Publication number
RU2017134055A3
RU2017134055A3 RU2017134055A RU2017134055A RU2017134055A3 RU 2017134055 A3 RU2017134055 A3 RU 2017134055A3 RU 2017134055 A RU2017134055 A RU 2017134055A RU 2017134055 A RU2017134055 A RU 2017134055A RU 2017134055 A3 RU2017134055 A3 RU 2017134055A3
Authority
RU
Russia
Application number
RU2017134055A
Other languages
Russian (ru)
Other versions
RU2714197C2 (ru
RU2017134055A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15305508.2A external-priority patent/EP3075381A1/en
Application filed filed Critical
Publication of RU2017134055A publication Critical patent/RU2017134055A/ru
Publication of RU2017134055A3 publication Critical patent/RU2017134055A3/ru
Application granted granted Critical
Publication of RU2714197C2 publication Critical patent/RU2714197C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2017134055A 2015-04-03 2016-04-01 Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций RU2714197C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15305508.2A EP3075381A1 (en) 2015-04-03 2015-04-03 Heterocyclic compounds and their use in preventing or treating bacterial infections
EP15305508.2 2015-04-03
EP16305069.3 2016-01-26
EP16305069 2016-01-26
PCT/EP2016/057274 WO2016156597A1 (en) 2015-04-03 2016-04-01 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (3)

Publication Number Publication Date
RU2017134055A RU2017134055A (ru) 2019-04-03
RU2017134055A3 true RU2017134055A3 (enExample) 2019-08-30
RU2714197C2 RU2714197C2 (ru) 2020-02-13

Family

ID=55646608

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017134055A RU2714197C2 (ru) 2015-04-03 2016-04-01 Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций

Country Status (14)

Country Link
US (1) US10501481B2 (enExample)
EP (1) EP3277277B1 (enExample)
JP (1) JP2018510198A (enExample)
KR (1) KR20170132316A (enExample)
CN (1) CN107438614B (enExample)
AU (1) AU2016239861A1 (enExample)
BR (1) BR112017020935A2 (enExample)
CA (1) CA2980395A1 (enExample)
CL (1) CL2017002482A1 (enExample)
MX (1) MX2017012545A (enExample)
RU (1) RU2714197C2 (enExample)
TW (1) TW201639854A (enExample)
WO (1) WO2016156597A1 (enExample)
ZA (1) ZA201706348B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
SG11201708047UA (en) 2015-04-03 2017-10-30 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
CN110402244B (zh) 2015-08-12 2023-02-03 因赛特公司 Lsd1抑制剂的盐
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3300736B1 (en) * 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
EP3604315A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
ES2960952T3 (es) 2018-08-09 2024-03-07 Antabio Sas Diazabiciclooctanonas como inhibidores de serina beta-lactamasas
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1107541A1 (ru) * 1982-12-03 1995-10-20 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 10-нитро-1,6,8-триазатрицикло [6,3,1,1] тридекан-2,5-дион
ES2127946T3 (es) 1993-12-29 1999-05-01 Pfizer Antagonistas de neurocinina diazabiciclica.
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
US20040009234A1 (en) * 2002-07-10 2004-01-15 Meisel Gerard M. Gastrointestinal compositions
CN101248073A (zh) * 2005-08-22 2008-08-20 塔加西普特公司 杂芳基-取代的二氮杂三环烷类、其制备方法及其应用
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Also Published As

Publication number Publication date
MX2017012545A (es) 2018-09-28
CN107438614A (zh) 2017-12-05
EP3277277B1 (en) 2021-01-06
CL2017002482A1 (es) 2018-04-20
AU2016239861A1 (en) 2017-10-12
US20180118765A1 (en) 2018-05-03
CN107438614B (zh) 2020-01-31
JP2018510198A (ja) 2018-04-12
CA2980395A1 (en) 2016-10-06
EP3277277A1 (en) 2018-02-07
RU2714197C2 (ru) 2020-02-13
KR20170132316A (ko) 2017-12-01
ZA201706348B (en) 2019-11-27
WO2016156597A1 (en) 2016-10-06
TW201639854A (zh) 2016-11-16
RU2017134055A (ru) 2019-04-03
US10501481B2 (en) 2019-12-10
BR112017020935A2 (pt) 2018-07-10

Similar Documents

Publication Publication Date Title
BR112017027103A2 (enExample)
BR112018004032A2 (enExample)
RU2017134055A3 (enExample)
BR112018002616A2 (enExample)
BR112018003428A2 (enExample)
BR112018002340A2 (enExample)
BR112017026964A2 (enExample)
AU2022228198B1 (enExample)
BE2015C047I2 (enExample)
BE2015C044I2 (enExample)
BR112017026635A2 (enExample)
CN303070058S (enExample)
BR0007672B1 (enExample)
CN303069124S (enExample)
CN303067815S (enExample)
CN303067162S (enExample)
CN303066656S (enExample)
CN303069473S (enExample)
CN303068013S (enExample)
BR0000695B1 (enExample)
CN303072234S (enExample)
BR0009182B1 (enExample)
BR0007747B1 (enExample)
BR0008789B1 (enExample)
BR0007688B1 (enExample)